Bio Rad Laboratories : Rad to Report Third-Quarter 2017 Financial Results Thursday, November 2, 2017
October 16, 2017 at 09:25 pm EDT
Share
HERCULES, Calif - October 13, 2017 - Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global provider of life science research and clinical diagnostic products, will report financial results for the third quarter 2017 on Thursday, November 2, 2017, following the close of the market. The company will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day.
To listen, call 855-779-9068 within the U.S. or 631-485-4862 outside the U.S., Conference ID: 96703879. You may also listen to the conference call live via a webcast that is available on the 'Investor Relations' section of our website under 'Quarterly Results ' at www.bio-rad.com. The webcast will be available for up to a year.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 8,350 people worldwide and had revenues exceeding $2 billion in 2016. For more information, please visit www.bio-rad.com.
Investor and Financial Contacts:
Christine Tsingos, Executive Vice President and Chief Financial Officer
Ron Hutton, Vice President and Treasurer
Bio-Rad Laboratories, Inc.
510-724-7000
Bio-Rad Laboratories Inc. published this content on 16 October 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 17 October 2017 01:24:03 UTC.
Original documenthttp://www.bio-rad.com/en-us/corporate/newsroom/bio-rad-to-report-third-quarter-2017-financial-results-thursday-november-2-2017
Public permalinkhttp://www.publicnow.com/view/C9E278D4C47D70747D8F33881B11C25C0031B1D2
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows:
- manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems;
- manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets;
- other (0.1%): in particular, manufacturing of analytical instruments.
At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore.
Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).